ENDPOINTS

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

4 months ago

News Briefing

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

4 months ago

News Briefing

Roivant discontinues lung disease drug; Bio-Thera, Intas make biosimilar deal

5 months ago

News Briefing

AffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s

5 months ago

News Briefing

Turnstone stops TIL studies; GH Research’s $150M offering

5 months ago

News Briefing

Tectonic to raise $185M; Acelyrin drops rights to Affibody drug

5 months ago

News Briefing

Ironwood's layoffs; Shionogi’s RSV pill succeeds in Phase 2

5 months ago

News Briefing

Curie.Bio has a new $340M fund; Layoffs at Benchling, I-Mab

5 months ago

News Briefing

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

5 months ago

People

Pharma

Trump blog: Federal agencies must give jobs back to fired probationary workers, judge rules

5 months ago

Pharma

FDA+

Boehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off assets

5 months ago

News Briefing

FDA delays decision on Stealth’s Barth syndrome drug; TargetRx raises $50M

5 months ago

News Briefing

Shanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc's $200M offering

5 months ago

News Briefing

FDA puts Atara’s INDs on hold after rejection; Ascletis' safety data for obesity pill

5 months ago

News Briefing

WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeutics

5 months ago

News Briefing

Boehringer's schizophrenia asset fails Phase 3; GSK buys organoid biotech

5 months ago

News Briefing

Hinge Bio's $30M raise; Keros reports additional issues in Phase 2 PAH trial

5 months ago

News Briefing

#JPM25 live blog day 3: PhRMA chief on reforming the IRA; Gilead weighs in on China dealmaking

5 months ago

Pharma

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

5 months ago

News Briefing

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

5 months ago

Pharma

Immunovant’s $450M private placement; Biomea becomes an obesity biotech

5 months ago

News Briefing

#JPM25 live blog day 1: How will Trump 2.0 impact the biopharma industry? Scott Gottlieb, Bob Nelsen share ...

5 months ago

Deals

Pharma

Stemson Therapeutics shutters; Insilico teams up again with Menarini

6 months ago

News Briefing

Numab extends its Series C; AnaCardio raises $19M for its heart failure drug

6 months ago

News Briefing

about the author

author articles

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

Roivant discontinues lung disease drug; Bio-Thera, Intas make biosimilar deal

AffyImmune’s layoffs; Henlius makes a biosimilar deal with Dr. Reddy’s

Turnstone stops TIL studies; GH Research’s $150M offering

Tectonic to raise $185M; Acelyrin drops rights to Affibody drug

Ironwood's layoffs; Shionogi’s RSV pill succeeds in Phase 2

Curie.Bio has a new $340M fund; Layoffs at Benchling, I-Mab

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

Trump blog: Federal agencies must give jobs back to fired probationary workers, judge rules

Boehringer merges cancer vaccine and oncolytic virus teams; Dantari sells off assets

FDA delays decision on Stealth’s Barth syndrome drug; TargetRx raises $50M

Shanghai Bao, Sichuan Biokin file IPOs in Hong Kong; Disc's $200M offering

FDA puts Atara’s INDs on hold after rejection; Ascletis' safety data for obesity pill

WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeutics

Boehringer's schizophrenia asset fails Phase 3; GSK buys organoid biotech

Hinge Bio's $30M raise; Keros reports additional issues in Phase 2 PAH trial

#JPM25 live blog day 3: PhRMA chief on reforming the IRA; Gilead weighs in on China dealmaking

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

#JPM25 live blog day 2: Nvidia makes it fun; The year's 10th megaround

Immunovant’s $450M private placement; Biomea becomes an obesity biotech

#JPM25 live blog day 1: How will Trump 2.0 impact the biopharma industry? Scott Gottlieb, Bob Nelsen share ...

Stemson Therapeutics shutters; Insilico teams up again with Menarini

Numab extends its Series C; AnaCardio raises $19M for its heart failure drug